Document:

Amendment # 3 to the Collaboration and Option Agreement

 Exhibit 10.8.3 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
 AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT 

THIS AMENDMENT #3 TO THE COLLABORATION AND
OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and
between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris
Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 RECITALS 
 WHEREAS, GlobeImmune and Celgene are parties to the Collaboration and Option Agreement, effective as of May 14, 2009, as amended on November 6, 2009 and February 9, 2010 (the
“Agreement”), which sets forth certain rights and obligations of both Parties relating to a certain collaboration, research and development activities for certain drug candidates and future drug programs; 

WHEREAS, Celgene and GlobeImmune desire to revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug
Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement; and 
 WHEREAS, capitalized terms used herein but not defined herein shall have the definitions set forth in the Agreement. 
 AGREEMENT 
 NOW, THEREFORE, GlobeImmune and Celgene agree as follows:

 1. Section 1.34 of the Agreement shall be deleted in its entirety and replaced with the following: 

“1.34 “Drug Candidate” means GI-4000, GI-6200, GI-3000, or GI-6300.” 

2. Section 1.53 of the Agreement shall be deleted in its entirety and replaced with the following: 

“1.53 “GI-6300” has the meaning set forth on Exhibit 1.34.” 

3. Section 3.2.1 of the Agreement shall be deleted in its entirety and replaced with the following: 

“3.2.1 Commencement of GlobeImmune Development Activities. GlobeImmune represents and warrants that

  
 1. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 
GlobeImmune, as of the Effective Date, has initiated (a) research Execution Copy activities for the Program containing GI-3000 and (b) research and development activities for the
Programs containing GI-4000 and GI-6200. GlobeImmune represents and warrants that GlobeImmune, as of the Amendment #3 Effective Date, has initiated research activities for the Program containing GI-6300. After the Effective Date, GlobeImmune
shall provide written notice to Celgene promptly after commencing any additional Development efforts for any Collaboration Compound. After exercise of a Celgene Program Option, upon the request of Celgene and agreement of GlobeImmune, in
GlobeImmune’s sole discretion, GlobeImmune may conduct Development activities with respect to the applicable Celgene Development Compound.” 
 4. Section 6.2.3 of the Agreement shall be deleted in its entirety and replaced with the following: 
 “6.2.3 Research and Development Milestones for Drug Candidates Other than the GI-4000 Program. 
 (a) GI-6200 and GI-3000. If Celgene exercises the Celgene Program Option with respect to a Program containing any of GI-6200 or GI-3000, in consideration of the research and Development work
performed by GlobeImmune under this Agreement for such GI-6200 or GI-3000 Program, as applicable, Celgene will pay, within thirty (30) days following the date of achievement of each milestone below (or, if achievement of such milestone is
within the control of GlobeImmune, within thirty (30) days following Celgene’s receipt of notice of the achievement of such milestone), to GlobeImmune the following milestone payments once each upon the achievement of the designated
milestone events per each Program. Each payment will be made once regardless of how many Collaboration Compounds in the Program may achieve each milestone event. If any milestone event relating to development (excluding Regulatory Approval
milestones) is achieved, all previously listed development milestone events, if not already achieved, shall be considered to be simultaneously achieved. 
  

					
	 Milestone Event
	  	Payment	 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 Total Per Drug Candidate Program
	  	 	[*	] 

  
 2. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 (b) GI-6300. If Celgene exercises the Celgene Program Option with respect to the
Program containing GI-6300, in consideration of the research and Development work performed by GlobeImmune under this Agreement for the Program for GI-6300, Celgene will pay, within thirty (30) days following the date of achievement of each
milestone below (or, if achievement of such milestone is within the control of GlobeImmune, within thirty (30) days following Celgene’s receipt of notice of the achievement of such milestone), to GlobeImmune the following milestone
payments once each upon the achievement of the designated milestone events per the Program for GI-6300. Each payment will be made once regardless of how many Collaboration Compounds in the GI-6300 Program may achieve each milestone event. If any
milestone event relating to development (excluding Regulatory Approval milestones) is achieved, all previously listed development milestone events, if not already achieved, shall be considered to be simultaneously achieved. 

 

					
	 Milestone Event
	  	Payment	 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 

  
 3. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 5. Exhibit 1.34 of the Agreement shall be deleted in its entirety and replaced with the
Exhibit 1.34 set forth in Appendix A attached hereto. 
 6. Exhibit 1.68 of the Agreement shall be deleted in its entirety and
replaced with the Exhibit 1.68 set forth in Appendix B attached hereto. 
 7. Pursuant to Section 8.2.8 of the Agreement,
Exhibit 1.57 of the Agreement shall be deleted in its entirety and replaced with the Exhibit 1.57 set forth in Appendix C attached hereto. 
 8. Pursuant to Section 8.2.8 of the Agreement, Exhibit 1.91 of the Agreement shall be deleted in its entirety and replaced with the Exhibit 1.91 set forth in Appendix D attached hereto. 

9. Schedule A of the Agreement shall be deleted in its entirety and replaced with the Schedule A set forth in Appendix E attached hereto.

 10. Celgene hereby acknowledges and agrees that the Collaboration Compound known as GI-10000 shall not be deemed a Drug
Candidate under the Agreement. GlobeImmune hereby acknowledges and agrees that (a) the Collaboration Compound known as GI-10000 may become a Future Program Compound under the Agreement (if the terms and conditions thereof of the Agreement are
met) and remains subject to the terms and conditions of the Agreement, including the obligations of Section 5.6 of the Agreement; and (b) this Amendment #3 shall not be deemed a termination of the Program containing GI-10000 under the
Agreement. 
 11. Except as otherwise amended by this Amendment #3, the Agreement shall remain in full force and effect as
presently written, and the rights, duties, liabilities and obligations of the Parties, as presently constituted, will continue in full effect. 
 12. In the event of any conflict between the terms of the Agreement and this Amendment #3, the terms of this Amendment #3 shall govern but only to the extent necessary to accomplish its purpose.

 13. This Amendment #3, together with the Agreement, constitutes the entire agreement between the Parties with respect to the
subject matter contained therein and herein, supersedes and replaces any and all prior and contemporaneous understandings, arrangements and agreements, whether oral or written, with respect to such subject matter. 

14. This Amendment #3 may be executed in counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. Signatures to this Amendment #3 transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and
pictorial appearance of this Amendment #3 shall have the same effect as physical delivery of the paper document bearing original signature. 

  
 4. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 [Signature Page Follows] 

  
 5. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 IN WITNESS WHEREOF,
GlobeImmune and Celgene have executed this Amendment #3 by their duly authorized representatives as of the Amendment #3 Effective Date. 
  

									
	GLOBEIMMUNE, INC.	 		 	CELGENE CORPORATION
					
	By:	 	 /s/ Timothy C. Rodell, M.D.
	 		 	By:	 	 /s/ Robert J. Hugin

					
	Name:	 	Timothy C. Rodell, M.D.	 		 	Name:	 	Robert J. Hugin
					
	Title:	 	President and CEO	 		 	Title:	 	Chairman and CEO

 [Signature Page to Amendment #3 to Collaboration and Option Agreement] 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Appendix A 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Exhibit 1.34 

Drug Candidates 
 GI-4000
means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI-4014, GI4015, GI4016 and GI4020 are part of the GI-4000 series and are the subject of IND No. [*]. 

GI-6200 means the series of Tarmogen products that solely express human carcinoembryonic antigen (CEA). GI-6207 is part of the GI-6200 series and means
the single Tarmogen product that is the subject of IND No. [*], and that solely expresses human CEA having a N610D mutation. 
 GI-3000 means
the series of Tarmogen products that solely express human epidermal growth factor receptor (EGFR). GI-3010 is part of the GI-3000 series and means the single Tarmogen product that is the subject of [*], and that solely expresses human EGFR lacking
the secretory signal sequence and the transmembrane domain. 
 GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is
part of the GI-6300 series and means the single Tarmogen product that may become the subject of [*] and that expresses a human brachyury protein. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Appendix B 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Exhibit 1.68 

Initial Development Plan 

GlobeImmune will be responsible for conducting all Development activities through Completion of the endpoint set forth below for each of the following
Drug Candidates: 
 Activities, endpoints and costs: 
 1) Drug Candidate - GI-4000 
 [*] 
 2) Drug Candidate - GI-6300 
 [*] 
 3) Drug Candidate - GI-6200 
 [*] 
 4) Drug Candidate - GI-3000 
 [*] 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Description of Clinical Trials referenced above: 

 

					
	 Drug Candidate
	  	Clinical Trial	 	Status
	 GI-4000
	  	[*]	 	
			
	 GI-6200
	  	[*]	 	
			
	 GI-6300
	  	[*]	 	

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Appendix C 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Exhibit 1.57 

GlobeImmune Licensed Patent(s) 
 Patents and Patent Applications Owned or Co-Owned by GlobeImmune: 
 [* 5 pages of text
omitted] 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Patents and Patent Applications Licensed from The Regents of the University of Colorado:

 [*] 
 Patents Licensed
from Washington Research Foundation: 
 [*] 
 Patents Licensed from National Institutes of Health: 
 [*] 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Appendix D 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Exhibit 1.91 

Platform Patents 

Patents and Patent Applications Owned or Co-owned by GlobeImmune: 
 [*2 pages of text omitted] 
 Patents and Patent Applications Licensed from The Regents
of the University of Colorado: 
 [*] 
 Patents Licensed from Washington Research Foundation: 
 [*] 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Appendix E 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Schedule A 

Third Party Agreement(s) 

[*]Option Extension Agreement between Registrant and Celgene Corporation

 Exhibit 10.8.5 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 July 23, 2012 
 Timothy C.
Rodell, M.D. 
 Chief Executive Officer and President 
 GlobeImmune, Inc. 
 1450 Infinite Dr. 
 Louisville CO 80027 
 Via Email to: terodell@globeimmune.com 

Dear Tim: 
 This letter agreement (“Option
Extension Agreement”) is to confirm the understanding that Celgene Corporation (“Celgene”) and GlobeImmune, Inc. (“Globeimmune”) have reached regarding the conduct of a phase 2/3 clinical trial with the GI-4000 Drug
Candidate in resected pancreas cancer (the “Phase 2/3 Trial”). 
 The Phase 2/3 Trial will be in resected pancreas cancer that shall
be subject to approval by the JRC pursuant to the Collaboration and Option Agreement, by and between Celgene and GlobeImmune, dated May 14, 2009, as amended (the “Agreement”). The phase 2 portion of the Phase 2/3 Trial will enroll a
minimum of 100 subjects and will use as a minimum a 1-year RFS endpoint for (a) prospectively validating a pre-selection proteomic signature which is associated with improved RFS and OS in the GI-4000 treated arm of GI-4000-02, and
(b) obtaining more precision on the total sample size needed for the phase 3 portion of the Phase 2/3 Trial. The complete details of the Phase 2/3 Trial protocol will be agreed to between the Parties through the JRC. 

The Celgene Program Option Period, as more fully described in the Agreement, shall be extended through to the Completion of the phase 2 portion of this
new Phase 2/3 Trial. Specifically, Celgene’s right to exercise the Celgene Program Option will be extended to [*] following the delivery by GlobeImmune of a new Initial Development Program Report that includes complete top line data from a
locked database using validated programs for the primary and secondary endpoints specific to the new phase 2 proof of concept portion of the new Phase 2/3 Trial and such additional information and access to GI-4000 Drug Candidate records as Celgene
may reasonably request consistent with Completion of a Clinical Trial. 
 In order for this Option Extension Agreement to be effective, Celgene
shall elect to purchase $4.9 million of Globelmmune’s equity securities (the “Option Extension Stock”) by March 31, 2013 as part of an offering that would provide GlobeImmune sufficient funds to pay the estimated initial phase 2
portion of the Phase 2/3 Trial through delivery of the Initial Development Program Report. If Celgene does not purchase the Option Extension Stock by March 31, 2013, this Option Extension Agreement shall be void and the terms of the Agreement
shall continue in full force. 
 As additional consideration for the Option Extension Agreement, the royalty rate for GI-4000 Licensed Products
at each tier under the terms of the Agreement will be increased, as follows, provided Celgene has purchased the Option Extension Stock, and GlobeImmune has satisfied the criteria set up above for the new Phase 2/3 Trial data as delivered in the new
Initial Development Program Report: 

  
 Page 1 of 2

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

			
	 Net Sales in the Territory in a Calendar Year for GI-4000
	  	Royalty Rate
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

 All capitalized terms used in this Option Extension Agreement but not defined herein shall have the meaning given to such
term in the Agreement. 
 Upon execution of this letter by both Parties, this Option Extension Agreement becomes effective as of the date of
this letter above, subject to Celgene’s purchase of the Option Extension Stock. 
 Except as set forth in this letter agreement, all
provisions of the Agreement shall remain in full force and effect. 
 Please execute this Option Extension Agreement by signing and dating in
the spaces below, thereby signifying your consent to the terms and conditions herein and return an executed copy to me. 
  

							
	Sincerely,	 		 	Acknowledged and Agreed:
			
	Celgene Corporation	 		 	GLOBEIMMUNE, INC.
				
		 		 	By:	 	/s/ Timothy C. Rodell, M.D.
				
		 		 	Name:	 	Timothy C. Rodell, M.D.
				
	/s/ Perry Karsen	 		 	Title:	 	CEO and President
	Name	 		 		 	
				
	Chief Operations Officer	 		 	Date:	 	26 July, 2012
	Title	 		 		 	

  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]